B+
Bull case
20%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
TMDX
TransMedics GroupCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$90.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+63.5
Score
AI commentary
The company-source evidence is concrete and the Q2 update is mixed: revenue, service growth, and the low end of guidance improved, while operating margin and EPS weakened. Pre-print analyst signals were mixed, but validated post-print revisions were not found. Available quote data show only modest movement around the Aug. 6 anchor, without enough evidence to attribute a durable market reaction to results or guidance. Social, options, short-interest, and employee sentiment data were not provided; the report remains a cautious monitoring view consistent with the deterministic negative prior.
RankAlpha Sentiment Codex - 2026-08-07
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-04eventQ2 results, raised guidance and post-print digestionMedium impact
The company reported Q2 revenue of $189.9 million, up 21% year over year, with product revenue up 16% and service revenue up 29%. It raised the low end of 2026 revenue guidance excluding PAD Aviation to $737-$757 million. Management also cited sequential gross-margin expansion, although operating margin declined to 12.5% from 23.2%. [#SEC-8K-2026-08-04]
2026-08-15catalystPost-earnings margin scrutinyHigh impact
Near-term sentiment may remain sensitive to earnings conversion: diluted EPS declined to $0.41 from $0.92 and operating income declined 35% year over year despite strong revenue growth. No verified post-print analyst estimate or target revisions were identified.
2027-08-07catalystTransplant-platform executionHigh impact
Longer-term upside depends on continued OCS utilization, ENHANCE Heart and DENOVO Lung progress, OCS Kidney development, European NOP expansion, and execution of the PAD Aviation logistics strategy. Management identified these as growth priorities, but timing and scale remain uncertain. [#SEC-8K-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology